Interesting COR Put And Call Options For August 2026

Cencora (COR) is the subject of two option strategies: selling a $340 put (bid $24.50) which would set an effective purchase price of $315.50 and is ~1% out‑of‑the‑money with a ~60% chance to expire worthless, implying a 7.21% return on cash (10.69% annualized). Alternatively, selling a $350 covered call (bid $28.80) against shares at $343.44 would cap upside at $350 and yields a 10.30% total return if called at August 2026, with a ~45% chance to expire worthless and an 8.39% premium boost (12.44% annualized). Implied volatilities are ~28% (put) and ~27% (call) versus a 22% realized trailing‑12m volatility; these metrics frame risk/reward for option sellers and covered‑call buyers rather than constituting market-moving corporate news.

Analysis

Market structure: The option chain signals active premium harvesting — put-sellers and covered-call sellers directly benefit (collecting ~7–8% yields to Aug 2026) while pure long-only holders face capped upside or assignment risk. At $343.44, the $340 put bid ($24.50) implies an unattractive immediate sale for short-term traders but a compelling cash-secured entry (~$315.50 basis) for patient buyers; flows of this type compress realized volatility vs implied (22% vs 27–28%). Cross-asset impact is limited but sustained put-selling can create asymmetric delta-hedging flows that slightly bid equities and compress credit spreads in near term; FX/commodities unaffected materially.

Risk assessment: Tail risks include regulatory shocks (CMS reimbursement or drug-pricing rulings) and contract loss with a large pharma client that could move COR >25% fast; contagion into peers (e.g., CAH) would amplify sector selloff. Immediate risk (days) is IV re-pricing around catalysts; short-term (weeks/months) is assignment risk and IV contraction hurting option longs; long-term (quarters/years) is margin pressure from pricing or integration failures. Hidden dependencies: heavy retail/options seller positioning can flip to gamma-driven volatility on a 7–12% move, and financing/assignment liquidity is a second-order operational risk.

Trade implications: Direct plays: use cash-secured $340 Aug 2026 puts to acquire COR at $315.50 (target position 1–3% of portfolio) or buy shares and sell $350 Aug 2026 covered calls to cap upside at ~10.3% to expiry. If you expect mean IV reversion, favor selling calendar/diagonal spreads (sell Aug 2026 $340 put, buy nearer-dated put as hedged short-put) to harvest theta while limiting tail. Pair trade: long COR vs short CAH (Cardinal Health) as relative value — COR overweight if you expect better scale/EBITDA leverage; size 0.5–1% net delta-neutral, rebalance monthly.

Contrarian angles: Consensus treats COR as a yield-enhancement target; what’s missed is asymmetric downside: implied vol premium (~+5–6% pts over realized) underprices regulatory/skew risk, so naked short-put exposure >2–3% portfolio is dangerous. Reaction may be underdone if a near-term earnings miss forces options repricing by +50% IV, making short-premium positions painful; conversely, if COR wins a contract and EPS exceeds by >7% IV could compress and let sellers pocket yields. Historical parallels: distributor episodes (2018–2019) show sudden margin shocks from reimbursement changes — position sizing and tail hedges are essential.

Key Decisions for Investors

• Sell 1x Aug 2026 COR $340 cash-secured put (collect ~$24.50) to establish a ~1–2% portfolio exposure; target effective buy price $315.50, max allocation if assigned 2–3% of portfolio. Roll or close if COR trades < $300 or if IV rises >40% (close at 30–50% loss on premium).
• If preferring equity exposure, buy COR up to 2% weight and sell Aug 2026 $350 covered calls (collect ~$28.80) to realize ~10.3% return to expiry; unwind/roll if COR > $370 or post-earnings move >+7%.
• Implement a hedged short-put diagonal: sell Aug 2026 COR $340 put and buy a nearer-dated (90–120 day) $320 put to cap tail loss; size to limit downside to ~8–10% portfolio move. Close or reprice if IV differential compresses to <3 vol points.
• Initiate a small pair trade: long COR / short CAH (Cardinal Health) equal-dollar, 0.5–1% net exposure to capture relative operational leverage. Set stop-loss on either leg at 12% and review after COR quarterly results (next 30–45 days); exit if COR guidance misses by >5% or CAH outperforms by >8%.